Eisai Co., Ltd.
Fiscal Year 2026 Q2 (Half-Year) Financial Results
Revenue showed an overall increasing trend. The pharmaceuticals segment was the main driver, led by key products Lenvima, Rekembi, and Dayvigo. Currency effects contributed to revenue and profit; core operating profit increased. Progress toward the full-year forecast is high at the 50% range.
Key Figures
- Revenue: 4,700 (Half-year results)
- Operating Income: 414
- Core Operating Profit: 431
- Profit for the Half-Year (Net Income): 313
- Progress vs Full-Year Forecast: 53.2% (Full-year 8,835)
AI要約
Overview of Results
For the second quarter of fiscal 2026, revenue was 4,700 hundred million yen, operating income was 414 hundred million yen, and core operating profit was 431 hundred million yen, all increasing year-over-year. The pharmaceuticals business performed well, with strong contributions from key products such as Lenvima, Rekembi, and Dayvigo. Growth was also achieved on a constant-currency basis excluding foreign exchange effects. The full-year forecast is revenue of 8,835 hundred million yen, with a progress rate of 53.2% toward the full-year target.
Segment Highlights and Outlook
The pharmaceuticals segment contributed approximately 8,621 hundred million yen in revenue. Major products in Japan, the U.S., China, EMEA, and EAGS continued to perform solidly. In particular, contributions from Lenvima, Dayvigo, and Rekembi remain important, and overall revenue growth considering currency impacts continues to be significant. Going forward, attention will be paid to trends with sensitivity to foreign exchange rates.
Revenue Trend
Operating Income Trend
Core Operating Profit Trend
Reported Segment Revenue Breakdown
Comparison of Guidance and Results
Eisai Co., Ltd.
Company overview · Stock price · Financial data · All IR
